Arcus Biosciences (RCUS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.72
- Estimate
- -$0.81
- Surprise
- +11.6%
- Revenue (period 2026-06-30)
- $33.0M
- Score today
- 4.7/10
Revenue source: xbrl.
How the report landed
Arcus Biosciences (RCUS) reported a narrower loss than forecast — adjusted EPS of -$0.72 against the -$0.81 estimate (a 11.6% beat on a still-unprofitable quarter).
Where TrendMatrix's rating stands now
TrendMatrix currently rates RCUS Sell at 4.7/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +11.6% surprise compares with a +1.8% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Concentration risk — Pipeline: casdatifan
- Concentration risk — Counterparty: Gilead
- Quality below floor (2.0 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $17.69
- Price target
- $35.67
- Stop
- $16.91
- Upside to target
- +101.6%
- Reward-to-risk
- 6.8:1
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
RCUS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.46B
- P/E (fwd)
- -6.2
- 52-week range
- $17.43–$31.73
- Off 52-week high
- 44.3%
- RSI (14)
- 33
- Volume vs avg
- 0.75×
- Score today
- 4.7/10